Chemomab CMO Aharon resigns; Weiner appointed Interim CMO

Chemomab Therapeutics Ltd.

Dr. Arnon Aharon resigned as CMO effective Feb 1, 2022; will continue 60 days and as senior advisor.
Dr. David M. Weiner appointed Interim CMO effective immediately, part-time, based in U.S.
Dr. Weiner has 25+ years experience; previously CEO of Amathus Therapeutics, CMO at Lumos Pharma and aTyr Pharma.
Resignation not due to any disagreement with company or board.
Chemomab advancing CM-101 clinical programs in fibrotic/inflammatory diseases.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Arnon Aharon

Chief Medical Officer

CMMB · Chemomab Therapeutics Ltd.

Effective: 2022-02-01
Filed: December 3, 2021, 6:59 PM ET

On November 29, 2021, Dr. Arnon Aharon notified Chemomab Therapeutics Ltd. (the “Company”) of his resignation as its Chief Medical Officer, which will enter into effect on February 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Arnon Aharon resigned as Chief Medical Officer at Chemomab Therapeutics Ltd..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On November 29, 2021, Dr. Arnon Aharon notified Chemomab Therapeutics Ltd. (the “Company”) of his resignation as its Chief Medical Officer, which will enter into effect on February 1, 2022.

View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-21-003771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.